Published in European journal of neurology
The coronavirus disease 2019 (COVID-19) pandemic challenges neurologists in counseling multiple sclerosis (MS) patients with respect to their risk for and by severe acute respiratory syndrome coronavirus 2 and in guiding disease-modifying treatment (DMT). The objective was to determine the frequency and distribution of currently known risk factors ...
Published in The Laryngoscope
Patients with tracheostomies have an anatomically altered connection between their upper and lower airways that could impact SARS-CoV-2 testing. Our goal was to evaluate for discordance in SARS-CoV-2 detection in hospitalized patients with COVID-19 and tracheostomies based on the site analyzed. Retrospective chart review. This single-institution st...
Published in European journal of neurology
The COVID-19 pandemic is a global public health issue. Neurological complications have been reported in up to one-third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. community-based...
Published in Journal of clinical pharmacology
The interaction of coronavirus disease (COVID-19) with the majority of common prescriptions is broadly unknown. The purpose of this study is to identify medications associated with altered disease outcomes in COVID-19. A retrospective cohort composed of all adult inpatient admissions to our center with COVID-19 was analyzed. Data concerning all ant...
Published in Vox sanguinis
Access to large pools of healthy adult donors advantageously positions blood component providers to undertake anti-SARS-CoV-2 seroprevalence studies. While numerous seroprevalence reports have been published by blood operators during the COVID-19 pandemic, details on the assay used has not been well documented. The objectives of this study were to ...
Published in European journal of neurology
The outbreak of the SARS-CoV-2 pandemic, caused by a previously unknown infectious agent, posed unprecedented challenges to healthcare systems and unmasked their vulnerability and limitations worldwide. Patients with long-term immunomodulatory/suppressive therapies, as well as their physicians, were and are concerned about balancing the risk of inf...
Published in Clinical & Translational Immunology
In this study, we found that a single dose of BNT162b2 vaccine generates a strong humoral (100%) and cellular response in convalescent COVID‐19 individuals (94%), and also in infection‐naïve healthcare workers with cross‐reactive immunity because of other coronaviruses (93%). However, this response was not observed in convalescent individuals with ...
Published in Clinical & Translational Immunology
This review summarises the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease.
Published in European Journal of Immunology
Antigen‐specific T‐cells are essential for protective immunity against SARS‐CoV‐2. We set up a semi‐automated whole‐blood Interferon‐gamma release assay (WB IGRA) to monitor the T‐cell response after stimulation with SARS‐CoV‐2 peptide pools. We report that the WB IGRA is complementary to serological assays to assess SARS‐CoV‐2 immunity.
Published in Febs Letters
Summary of main metabolic changes in SARS‐CoV‐2‐infected Huh7 cells at 72 hpi. The mitochondrial ETC and oxidative phosphorylation are downregulated, reducing ATP production from the TCA cycle but potentially providing protection from apoptosis. The components of the TCA producing intermediates for viral amino acid synthesis are upregulated. While ...
